ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas

Journal of Pathology

Volumn 214, Issue 4, 2008, Pages 410-414

  Venturini, L ^a   Erdas, R ^a   Costa, A ^a   Gronchi, A ^a   Pilotti, S ^a   Zaffaroni, N ^a   Daidone, M G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

ALT associated promyelocytic leukaemia bodies (APBs) detection; Alternative lengthening of telomeres (ALT) mechanism; Archival specimens; Liposarcoma; Telomere maintenance

Indexed keywords

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CELL NUCLEUS INCLUSION BODY; CHROMOSOMAL INSTABILITY; CHROMOSOME SIZE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA BODY; TELOMERE;

ADULT; CRYOPRESERVATION; DISEASE PROGRESSION; FORMALDEHYDE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOSARCOMA; PARAFFIN EMBEDDING; PHENOTYPE; REPRODUCIBILITY OF RESULTS; TELOMERE;

EID: 40349085803     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2288     Document Type: Article

References (11)

1. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001;10:677-685.
2. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumours and tumour-derived cell lines. Nature Med 1997;3:1271-1274.
3. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nature Genet 2000;26:447-450.
4. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-4179.
5. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003;63:1759- 1763.
6. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006;66:8918-8924.
7. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, et al. A robust assay for alternative lengthening of telomeres in tumours shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-225.
8. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician 1983;32:307-317.
9. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-838.
10. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004;41:155-162.
11. Johnson JE, Varkonyi RJ, Schwalm J, Cragle R, Klein-Szanto A, Patchefsky A, et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 2005;11:5347-5355.